Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
Author:
Publisher
Elsevier BV
Subject
Pharmacology
Reference165 articles.
1. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3;Abel;JVI insight,2013
2. MicroRNA and cancer--a brief overview;Acunzo;Adv Biol Regul,2015
3. MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma;Alver;Oncotarget,2016
4. The mitogen-activated protein kinase pathway in melanoma part I - activation and primary resistance mechanisms to BRAF inhibition;Amaral;Eur. J. Cancer,2017
5. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma;Amin;J. Immunother Cancer,2016
Cited by 69 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib);Cell Communication and Signaling;2024-08-23
2. Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight;Melanoma Research;2024-07-22
3. A comprehensive overview of the molecular features and therapeutic targets in BRAFV600E‐mutant colorectal cancer;Clinical and Translational Medicine;2024-07
4. Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells;Cell Communication and Signaling;2024-05-22
5. Cold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro;Journal of Biophotonics;2023-12-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3